Report
Dr Jonas Peciulis

A leading remote cardiac monitoring player

LifeWatch specialises in ECG-based remote cardiac monitoring services and is one of the leading companies in this space in the US, with around four million patients monitored to date. The company had a solid FY15, with 8.3% adjusted revenue growth and its strongest EBITDA in six years. However, 2016 was turbulent, mainly as a result of costly but one-off legal settlements. Having streamlined its cost base and left the legacy issues behind it, LifeWatch is now well placed to capitalise on healthy market growth, returning to profitability in FY17; we value it at CHF258m ($250m).
Underlying
LifeWatch AG

Lifewatch is a specialist in telemedicine monitoring services and a developer, manufacturer and marketer of wireless healthcare technologies and products. These services and devices are used to assess a broad array of physiological functions that allow patients to be monitored and treated in their normal, everyday environment. Co.'s primary service offering is cardiac monitoring, as well as monitors for the following services: ACT, Event, Holter and Pacemaker. Co. functions in two business segments: Monitoring services and the sale of systems.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Dr Jonas Peciulis

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch